SPOTLIGHT -
Eyetech Pharmaceuticals Inc. and Pfizer Inc. have filed a new drug application with the FDA for the 0.3 mg dose of pegaptanib sodium injection (Macugen) as a treatment for AMD (also see Page 46 in this issue).
Vision Council release results of their Provider InSights research study for Q3
Week in Review - November 12, 2023
Rising pollution levels in Delhi trigger 40% surge in eye problems
Diabetic Macular Edema – Considering Pathogenesis in Treatment Selection
Orbis International online course equips healthcare workers to identify glaucoma signs
Kingfisher study: Safety and efficacy of brolucizumab for DME